Lai et al. [161] demonstrated that GBMs carrying the IDH mutation could potentially emerge from neural cells on a committed lineage, whereas gliomas lacking the IDH mutation might arise from neural stem cells (NSCs). Here, IDH2 is linked to central nervous system cancer.